Compare SYSCO Corporation (SYY) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SYSCO Corporation vs BIO-TECHNE Corp — how do they compare? SYSCO Corporation trades at $84.25 (market cap $40.14B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: SYSCO Corporation is far larger — about 3.6× BIO-TECHNE Corp's market cap, and SYSCO Corporation pays the higher dividend (2.62%). Which is the better fit depends on your goals.
| SYY | TECH | |
|---|---|---|
Market Cap | $40.14B | $11.24B |
Sector | Consumer Staples | Health |
52-Week High | $91.16 | $72.29 |
52-Week Low | $69.30 | $43.31 |
Enterprise Value | $53.32B | $11.32B |
Dividend Yield | 2.62% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sysco (SYY) trades at $84.29, showing minimal daily movement (-0.07%) amid bullish technical signals and strong institutional support. The company delivered solid Q4 2026 results with EPS of $1.53 beating estimates, supported by 4.7% revenue growth and improved operational efficiency. With a P/E of 23.03 and ROE of 78.16%, fundamentals remain robust despite modest net margins of 2.08%. Recent news highlights supply chain initiatives and steady customer demand driving positive outlook.
Outlook remains positive with analyst consensus target of $88.25 (4.7% upside) and 60% buy ratings. Key opportunities include continued market share gains and cost efficiency benefits, while risks involve margin pressure from inflation and competitive food distribution landscape. The stock presents a balanced growth opportunity with defensive characteristics in foodservice distribution.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
